EGFR and non-small cell lung carcinoma: Mutations in epidermal growth factor receptor (EGFR) play critical roles in the pathogenesis of non–small cell lung cancer (NSCLC), and they are highly associated with sensitivity to tyrosine kinase inhibitors.